How Does Esketamine (Spravato) Work?
· Updated November 2026 · Aazaz Haq, MD
Patients often ask me why esketamine can help in days when their antidepressants took weeks and still did not work. The short answer is that esketamine works on a different system in the brain. Here is how I explain it in the office.
The short answer
Esketamine is one of the two mirror-image forms of ketamine. It works on glutamate rather than serotonin, and appears to help the brain rebuild connections quickly, which is why some people improve within days. It is FDA-approved for treatment-resistant depression, given only in certified clinics with two hours of monitoring, and it helps a meaningful share of people, though not everyone.
One of ketamine's two hands
Many molecules come in two mirror-image forms, like your left and right hands. Same parts, but they do not line up on top of each other. Ketamine is one of these molecules. The ketamine used in hospitals is a 50/50 mix of both forms. Esketamine is one of those two hands, separated out. It binds more strongly to its main target in the brain, which is why the doses are smaller.
Spravato is the brand name for esketamine given as a nasal spray. The FDA approved it in 2019 for treatment-resistant depression and in 2020 for depression with suicidal thoughts. In January 2025, the FDA also allowed it to be used on its own, without a daily oral antidepressant, for adults who have not done well on at least two antidepressants.
A different system than standard antidepressants
Most antidepressants, like sertraline or bupropion, work on serotonin, norepinephrine or dopamine. Those systems take weeks to adjust, and for many people they never adjust enough.
Esketamine works on glutamate, the brain's main "go" signal. It blocks a receptor called the NMDA receptor. That briefly causes a burst of glutamate activity in areas that regulate mood. The burst switches on growth signals that help nerve cells build new connections, called synapses.
In long-standing depression, connections in some of these circuits appear to thin out. Researchers believe esketamine and ketamine help rebuild them quickly, which may be why some people feel a change within hours to days rather than weeks.
I want to be careful here. This is the leading explanation, supported by animal studies and human imaging, but the full picture is still being worked out. What we know with more certainty comes from clinical trials: esketamine helps a meaningful share of people who did not respond to other treatments.
What the trials show
In the trial that led to approval, adults with treatment-resistant depression who added esketamine to a new antidepressant improved more over four weeks than those who added a placebo spray. In a later study of people who were doing well on esketamine, those who stayed on it were about half as likely to relapse as those switched to placebo.
The strongest comparison came in 2023. In a large trial, esketamine was compared with quetiapine, a common add-on medication for depression. After eight weeks, about 27% of people on esketamine were in remission compared with about 18% on quetiapine. That is a real difference. It also tells you that esketamine does not work for everyone, and I say that plainly before anyone starts.
Why it is given in the clinic
Esketamine can cause dissociation (feeling detached or dreamlike), sedation, nausea and a temporary rise in blood pressure. For that reason, federal safety rules require that every dose be taken in a certified clinic, with monitoring for at least two hours. You cannot drive until the next day after a full night's sleep.
The feeling during treatment does not tell you whether it is working. The goal is improvement in your symptoms and your life over the following weeks, not a particular experience in the chair.
The schedule
Treatment usually starts twice a week for four weeks, then moves to weekly, then weekly or every other week for people who are doing well. We track depression scores along the way so we can tell whether it is helping and adjust the plan if it is not.
If you want to see this visually, our guide to why ketamine and Spravato can work in days walks through it step by step, and your Spravato treatment day shows what a visit looks like.
Is it right for you?
That depends on your diagnosis, what you have already tried, your blood pressure and medical history, any history of substance use, and your insurance. Those are questions for a psychiatric evaluation, not a website. If you would like to talk through whether esketamine makes sense, request a consultation call and our patient advocate will help you decide on next steps.
Questions I hear often
Does it change who I am?
No. The dissociative feeling during treatment wears off within the monitoring period. What people describe over the following weeks is feeling more like themselves: able to get up, think more clearly, and take an interest in things again.
Do I have to stop my antidepressant?
Usually not. Many people continue their current antidepressant during esketamine treatment, and since 2025 esketamine can also be used on its own. We decide together based on how your current medication is helping and how well you tolerate it.
Is it addictive?
Ketamine and esketamine can be misused, and esketamine carries an FDA boxed warning about this. That is one reason every dose is taken in the clinic and nothing is sent home. In a monitored medical setting, with screening for substance use history, the risk is managed carefully. Our guide on ketamine and addiction covers this in detail.
How will I know if it is working?
We measure your symptoms with standard depression scales at regular visits. Many people who respond notice changes within the first two to four weeks: better sleep, more energy, less heaviness in the morning. If there is little change after the first phase of treatment, we talk honestly about whether to continue or try something else.
Who should not take esketamine
Esketamine is not appropriate for people with certain blood vessel conditions, such as an aneurysm, or a history of bleeding in the brain. Uncontrolled high blood pressure, recent heart problems, psychosis and active substance use problems also need careful review and may rule it out. It is not used during pregnancy. These are exactly the questions a psychiatric evaluation is designed to answer.
References
- Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression (TRANSFORM-2). Am J Psychiatry. 2019. PubMed
- Daly EJ, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention (SUSTAIN-1). JAMA Psychiatry. 2019. PubMed
- Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression (ESCAPE-TRD). N Engl J Med. 2023. PubMed
- Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012. PubMed